High levels of baseline serum IL-10 are associated with reduced clinical benefit from first-line immune checkpoint inhibitor therapy in advanced renal cell carcinoma

Immune checkpoint inhibitor (ICI) became a standard treatment for advanced renal cell carcinoma (RCC). However, clinically valid biomarkers of therapeutic outcome are lacking. We investigated the role of interleukin-10 (IL-10) as a predictive biomarker for first-line ICI therapy in patients with adv...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Youngun, Yang, Hannah, Lee, Won Suk, Cheon, Jaekyung, Sang, Yun Beom, Kang, Beodeul, Chon, Hong Jae, Kim, Chan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2023
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10158513/
https://www.ncbi.nlm.nih.gov/pubmed/37151396
http://dx.doi.org/10.7150/jca.81384

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10158513/
https://www.ncbi.nlm.nih.gov/pubmed/37151396
http://dx.doi.org/10.7150/jca.81384

Ejemplares similares